Anti-IgE therapy with omalizumab works by binding to (and thereby blocking) the IgE receptors located on the surface of all mast cells and basophils. Omalizumab interrupts IgE's signal to trigger the inflammatory response responsible for the symptoms of allergic asthma.

Anti-IgE therapy has been shown to reduce asthma attacks and lessen symptoms in some people with allergic asthma.

Facts about omalizumab (Xolair):

• Used only in those with elevated IgE in the bloodstream and a positive skin test to an allergen.
• Used in those with allergic asthma who cannot be controlled with corticosteroids.
• Administered as a weekly subcutaneous injection at the doctor's office.

Your doctor can determine if you are a candidate for treatment with omalizumab.